Heart failure with preserved ejection fraction: emerging drug strategies
about
Heart Failure with Preserved Ejection Fraction - Concept, Pathophysiology, Diagnosis and Challenges for TreatmentAge-associated pro-inflammatory remodeling and functional phenotype in the heart and large arteriesWhat can we learn about treating heart failure from the heart's response to acute exercise? Focus on the coronary microcirculationShould there be sex-specific criteria for the diagnosis and treatment of heart failure?Diurnal rhythms of serum and plasma cytokine profiles in healthy elderly individuals assessed using membrane based multiplexed immunoassay.Excess Linoleic Acid Increases Collagen I/III Ratio and "Stiffens" the Heart Muscle Following High Fat Diets.Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.Heart failure with preserved ejection fraction: Defining the function of ROS and NO.LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation.Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.Abnormal calcium homeostasis in heart failure with preserved ejection fraction is related to both reduced contractile function and incomplete relaxation: an electromechanically detailed biophysical modeling study.In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction.Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.A New Mechanism of Action in Heart Failure: Angiotensin-Receptor Neprilysin Inhibition.
P2860
Q26747554-CF105CAF-984B-4970-8DEB-ECD4DF7BE3E2Q28080582-B3D71811-D566-46A8-AC17-51F15BB7C067Q28083350-BB08FE87-6223-4599-906B-96C74B152A4EQ30442043-F7B1420E-DC8E-4951-A2CC-25CBCBA247E7Q35552567-94A1332F-542A-4DC2-B8CE-BDA0F8B4FD18Q36281656-7CC5AD5B-C2C2-4446-81AC-A805B51514CDQ37696624-AEDA9F09-BB84-439C-B447-754C6364F7F0Q38482322-D215A05B-668C-4D7E-BD0A-7FE4F27CD32FQ38568202-571C38B3-D749-4B3A-8674-BC57534B87C3Q40286144-1F09E4A2-B2A0-43EA-B42B-538A14F3DA67Q41025346-F9A70754-3A55-491D-8940-0A5608F1FD36Q43195701-8575E305-50A5-4049-B7D0-EAC558D27DFAQ54963943-AA5063AD-FF19-45DC-8E89-646CB876BE89Q55029995-E334D36A-8F06-4AEB-961D-9A52F97C1C16Q55311599-8A25FACA-8098-4B21-862A-DFD9D31EEAAC
P2860
Heart failure with preserved ejection fraction: emerging drug strategies
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Heart failure with preserved ejection fraction: emerging drug strategies
@ast
Heart failure with preserved ejection fraction: emerging drug strategies
@en
Heart failure with preserved ejection fraction: emerging drug strategies
@nl
type
label
Heart failure with preserved ejection fraction: emerging drug strategies
@ast
Heart failure with preserved ejection fraction: emerging drug strategies
@en
Heart failure with preserved ejection fraction: emerging drug strategies
@nl
prefLabel
Heart failure with preserved ejection fraction: emerging drug strategies
@ast
Heart failure with preserved ejection fraction: emerging drug strategies
@en
Heart failure with preserved ejection fraction: emerging drug strategies
@nl
P2093
P2860
P1476
Heart failure with preserved ejection fraction: emerging drug strategies
@en
P2093
Danielle V da Costa
Fouad A Zouein
George W Booz
Mazen Kurdi
P2860
P356
10.1097/FJC.0B013E31829A4E61
P407
P577
2013-07-01T00:00:00Z